Chloride channel accessory 1 (CLCA1) is considered a potential prognostic biomarker for colon adenocarcinoma (COAD). The objective of this research was to develop two pathomics models to predict CLCA1 expression from hematoxylin-eosin (H&E) stained p...
We report a proof-of-concept diagnostic strategy that integrates multiplexed Raman-tagged antibody labeling with label-free surface-enhanced Raman spectroscopy (SERS) and machine learning (ML) to improve the detection of ovarian cancer via extracellu...
DNA metabolism genes play pivotal roles in the regulation of cellular processes that contribute to cancer progression, immune modulation, and therapeutic response in prostate cancer (PC). Understanding the mechanisms by which these genes influence th...
Exhaled breath samples of lung cancer patients (LC), tuberculosis (TB) patients and asymptomatic controls (C) were analyzed using gas chromatography-mass spectrometry (GC-MS). Ten volatile organic compounds (VOCs) were identified as possible biomarke...
Hepatitis B virus (HBV) infection is a major driver of hepatocellular carcinoma (HCC), yet the mechanisms by which HBV triggers HCC and how it interacts with the immune system remain largely undefined. In this study, 53 immune-related key genes invol...
Oral cancer is among the top malignancies and the leading cause of death worldwide. Poor outcomes are attributed to local recurrence and distant metastasis of disease. There is an urgent need to identify the potential biomarkers that may help in prog...
Gliomas are the most prevalent malignant primary brain tumors and present diagnostic challenges due to varying survival rates and treatment responses between low-grade gliomas (LGGs) and high-grade gliomas (HGGs). Accurate classification is crucial f...
Extracellular vesicles (EVs) exhibit extensive glycosylation modifications, which are promising biomarkers for gastric cancer (GC). However, EV glycomics and the potential application of EV glycosylation patterns in liquid biopsy remain largely unexp...
Nearly 40 % of individuals will be diagnosed with cancer in their lifetime, translating to an estimated 20 million new cases annually. Despite remarkable therapeutic advances, only 15-20 % of patients achieve durable responses to immunotherapy, and t...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.